Information Provided By: 
Fly News Breaks for February 19, 2020
AYX
Feb 19, 2020 | 08:10 EDT
Citi analyst Tyler Radke raised the firm's price target on Alteryx to $202 from $150 and keeps a Buy rating on the shares. The analyst increased his estimates following the company's Q4 results, which he notes saw a modest reacceleration in billings and better than expected guidance. He sees positive catalysts ahead following the "strong" Q4 results.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
